Growing cannabis — indoor, outdoor, legal status

How do indoor and outdoor compare? Which genetics dominate Switzerland? This hub bundles every relevant growing and genetics guide.

The cultivation hub covers indoor, outdoor and greenhouse growing across Swiss climate zones (Plateau, Ticino, northern Alps) — substrate, lighting, VPD control and strain choice under 1 % THC. We map the legal boundary to Narcotics-Act licensing and typical yields per m².

Definition and context

Cultivation covers every stage from genetics, vegetative and flowering phases, to harvesting, drying, and curing. In fact, a significant portion of the quality is only established after the harvest.

The situation in Switzerland

In Switzerland, cultivating cannabis with less than 1% THC is permitted subject to cantonal regulations, whereas growing THC cannabis remains a punishable offense. Commercial CBD cultivation must be reported and is subject to official controls—one reason why Swiss indoor products maintain a consistently high standard.

What this means in practice

Crucial to product quality is a slow drying process at around 18–20 °C and 55–60% humidity, as well as curing for two to four weeks. Fast-dried bud smells of hay, loses its terpenes, and becomes harsh—which is easily detectable even without a laboratory test.

Frequently asked questions

Am I allowed to grow cannabis in Switzerland?

Only strains with less than 1% THC and in compliance with cantonal regulations. Cultivating THC cannabis remains a punishable offense.

What is curing?

The controlled aging process after drying. It breaks down chlorophyll, significantly improving both aroma and smoking quality.

Why is indoor cannabis more expensive?

Lighting, climate control, and labor costs are higher—in return, the active ingredient content, structure, and terpene profile are much more predictable.

Background and development

Switzerland's relationship with cannabis cultivation changed fundamentally in 2011 when the Federal Narcotics Act (BetmG) was revised to establish the unique 1% total THC threshold. This liberal limit birthed a highly sophisticated domestic CBD farming industry, regulated closely by the Federal Office of Public Health (FOPH) and Swissmedic. While cultivating high-THC cannabis for recreational use remains generally prohibited under the BetmG, the landscape is shifting. On 1 August 2022, Switzerland legalized medical cannabis by prescription, removing Swissmedic import barriers and simplifying patient access. Simultaneously, the FOPH approved pioneering, strictly monitored pilot studies in Basel, Zurich, Bern, Lausanne, and Geneva. These scientific trials allow legal, local cultivation of high-THC cannabis specifically for registered study participants, laying the groundwork for potential future adult-use regulations. Today, Swiss growers operate under some of the world's most rigorous agricultural and quality-control standards.

Distinctions and misconceptions

A frequent point of confusion in Switzerland is the distinction between cultivating industrial hemp, low-THC cannabis (CBD), and medical strains. Many assume that because CBD flowers look, smell, and taste identical to high-THC cannabis, their cultivation is completely unregulated. In reality, commercial CBD cultivation must be officially reported to cantonal agricultural authorities, and products are heavily scrutinized to ensure they remain under the 1% THC threshold. Another common misconception is that growing a small number of high-THC plants at home for personal use is legal or decriminalized. While possessing up to 10 grams of high-THC cannabis is a minor infraction carrying a fixed penalty of 100 CHF rather than a criminal record, cultivating even a single high-THC plant remains a punishable offense under the BetmG. Finally, people often confuse agricultural CBD regulations with Swiss road safety laws; driving under the influence of any cannabis remains strictly prohibited, with a zero-tolerance limit of 1.5 micrograms of THC per litre of blood.

Decision guide for Switzerland

For an adult in Switzerland looking to engage with cannabis, clear decision pathways depend entirely on legal status and growing space. First, ensure you only cultivate strains certified to yield under 1% total THC. If choosing to grow CBD at home, decide between outdoor and indoor. Outdoor cultivation is highly cost-effective, relying on Swiss sunlight, but restricts you to one harvest per year and leaves plants vulnerable to fluctuating alpine weather. Indoor cultivation offers total environmental control, ensuring top-tier terpene profiles and dense buds, but requires investing in expensive grow lights, ventilation, and odor-filtering systems, which significantly increases electricity costs. Avoid buying seeds or clones from unverified sources that lack laboratory certificates, as exceeding the 1% THC limit constitutes a violation of the BetmG. Additionally, always check your local cantonal and municipal fire safety and tenancy regulations, as landlords can legally restrict indoor growing setups due to humidity and fire hazards.

Can I grow medical cannabis at home if I have a doctor's prescription?

No. Although the medical use of cannabis with over 1% THC has been legal by prescription since August 2022, patients are strictly prohibited from growing their own high-THC medical plants at home. Prescribed cannabis must be obtained exclusively through authorized Swiss pharmacies. Medical cultivation is only permitted for licensed commercial manufacturers who hold exceptional permits issued by the Federal Office of Public Health and Swissmedic under tight security.

Do I need to notify Swiss authorities if I grow low-THC cannabis for private use?

Private, non-commercial cultivation of CBD cannabis with less than 1% THC does not need to be reported to the FOPH or cantonal authorities. However, if you plan to sell your harvest or grow CBD commercially, you must register your operation with the competent cantonal agricultural office. Regardless of scale, growers must ensure their plants never cross the legal 1% THC threshold to avoid criminal liability.

Explore this topic further

These guides explain the background and address practical questions in the Swiss context.

Key figures

  • 220’000+ — Swiss adults regularly consume cannabis (BAG · Suchtmonitoring 2024)
  • 36% — of 15–34 year-olds have tried cannabis (EMCDDA · Country Report Switzerland 2024)
  • CHF 582M — estimated Swiss cannabis black-market revenue per year (Uni Genf · Cannabis Market Estimate 2023)
  • 7 — cities with active or approved pilot projects (BAG · Cannabis Pilotversuche 2026)

Current research

  • Cannabis use in Switzerland — Addiction Monitoring 2024 — Sucht Schweiz, BAG · 2024
  • European Drug Report — Cannabis Chapter — EMCDDA, EUDA · 2024
  • WHO Expert Committee on Drug Dependence — Cannabis Review — WHO ECDD, WHO · 2023